CBER Index A to C | D to F | G to I | J to M | N to P | Q to S | T to Z Koate-DVI (Antihemophilic Factor (Human)) Kogenate FS, Helixate FS (Antihemophilic Factor (Recombinant)) Labeling for Biological Products Laws Letters Letters to Industry / Healthcare Providers Notice of Initiation of Disqualification Proceedings Letters Violative Advertising & Promotional Labeling Letters Warning Letters Leukine, Prokine (Sargramostim) Licensed Establishments and Products Licensed Products - Approval Information Lyme Disease Vaccine (Recombinant OspA) (LYMErix) LYMErix (Lyme Disease Vaccine (Recombinant OspA) Lymphocyte Immune Therapy (LIT) Manual of Regulatory Standard Operating Procedures and Policies Medical Device User Fee and Modernization Act (MDUFMA) MedMira Reveal G2 Rapid HIV-1 Antibody Test (Medmira Labs) Med Watch - The FDA Medical Products Reporting Program Meetings Memoranda to Blood Establishments Mercury     [Thimerosal] Monkeypox Mission / Vision MMWR Publications Myoscint (Imciromab pentetate)

Updated June 25, 2004

CBER Home Page | CBER A-Z Index | CBER Search | Contact CBER FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page FDA / Center for Biologics Evaluation and Research